Our investigational product candidates, AL101 and AL102, are designed to target cancer at the source by addressing the underlying key drivers of tumor growth. Both aim to target Notch pathway activation using gamma secretase inhibitors (GSIs).
These product candidates are being studied for a variety of tumors:
Adenoid Cystic Carcinoma (ACC)
Triple Negative Breast Cancer (TNBC)
T-cell Acute Lymphoblastic Leukemia (T-ALL)
In addition to the Notch pathway, gamma secretase may be targeted to increase levels of B-cell maturation antigen (BCMA), which is expressed in most multiple myeloma patients.
Our investigational lead candidate is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in the Phase 2 ACCURACY clinical trial for recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. In addition, we intend to commence Phase 2 clinical trials of AL101 for the treatment of recurrent/metastatic triple negative breast cancer (R/M TNBC) and relapse/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL).
The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.
Ayala is developing AL102 for the treatment of desmoid tumors, which are rare, disfiguring and often debilitating types of soft tissue tumors. We intend to commence a Phase 2 trial of AL102.
We are also collaborating with Novartis (Novartis International Pharmaceutical Limited) to develop AL102 for the treatment of multiple myeloma (MM) in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. Evaluation of AL102 as an inhibitor of the Notch pathway for additional indications is ongoing.
A Phase 2 ACCURACY clinical trial for recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations is currently underway.
Phase 2 clinical trials of AL101 for the treatment of recurrent and metastatic triple negative breast cancer (R/M TNBC) and relapse refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) will be initiated in the future.